Top

World Journal of Surgery

Published in:

01-08-2016 | Original Scientific Report

Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer

Authors: Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Hiroyuki Shinchi, Shoji Natsugoe

Published in: World Journal of Surgery | Issue 8/2016

Abstract

Background

Identifying novel predictors of hematogenous metastasis is essential to select optimal therapeutic strategies for pancreatic cancer. The goal of this study was to clarify the clinical implications of p53 and platelet-derived growth factor receptor-β (PDGFR-β) in pancreatic cancer using immunohistochemistry (IHC).

Methods

Specimens obtained by surgical resection and endoscopic ultrasound-guided fine-needle aspiration (EUS–FNA) of the primary tumor were used for IHC. EUS–FNA was performed before any treatment. We analyzed the clinical implications of p53 and PDGFR-β IHC. We also performed a comparative analysis of the IHC findings between surgical and EUS–FNA specimens.

Results

This study involved 149 patients (120 who did not receive and 29 who received preoperative therapy). EUS–FNA specimens were obtained from 20 patients without preoperative therapy and 20 patients with preoperative therapy. Abnormal p53 and high PDGFR-β expression was significantly correlated with a high incidence of hematogenous metastasis (p < 0.001) and poor postoperative survival (p = 0.006). In patients without preoperative therapy, the results for p53 and PDGFR-β staining were concordant between surgical and EUS–FNA specimens in 95 % of the cases. In patients with preoperative therapy, 80 and 70 % of the patients showed consistent p53 and PDGFR-β expression between surgical and EUS–FNA specimens, respectively.

Conclusions

Pancreatic cancer patients with simultaneous abnormal p53 and high PDGFR-β expression have a significantly higher risk of hematogenous metastasis and a poor prognosis after surgery. IHC evaluation using EUS–FNA specimens may be able to identify patients with highly metastatic pancreatic cancer who may benefit from aggressive therapeutic intervention.

Vincent A, Herman J, Schulick R et al (2011) Pancreatic cancer. Lancet 378:607–620CrossRefPubMedPubMedCentral

Ying JE, Zhu LM, Liu BX (2012) Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol 18:736–745CrossRefPubMedPubMedCentral

Cameron JL, Riall TS, Coleman J et al (2006) One thousand consecutive pancreaticoduodenectomies. Ann Surg 244:10–15CrossRefPubMedPubMedCentral

Yachida S, Iacobuzio-Donahue CA (2009) The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med 133:413–422PubMed

Rose JB, Rocha FG, Alseidi A et al (2014) Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol 21:1530–1537CrossRefPubMed

Ferrone CR, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17CrossRefPubMedPubMedCentral

Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806CrossRefPubMedPubMedCentral

Yachida S, Iacobuzio-Donahue CA (2013) Evolution and dynamics of pancreatic cancer progression. Oncogene 32:5253–5260CrossRefPubMed

Obata A, Eura M, Sasaki J et al (2000) Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer 89:187–193CrossRefPubMed

10.

Freed-Pastor WA, Mizuno H, Zhao X et al (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244–258CrossRefPubMedPubMedCentral

11.

Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233–240CrossRefPubMed

12.

Oshima M, Okano K, Muraki S et al (2013) Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 258:336–346CrossRefPubMed

13.

Shin SH, Kim SC, Hong SM et al (2013) Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas 42:216–222CrossRefPubMed

14.

Kim H, Saka B, Knight S et al (2014) Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res 20:1865–1872CrossRefPubMedPubMedCentral

15.

Nenutil R, Smardova J, Pavlova S et al (2005) Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207:251–259CrossRefPubMed

16.

Pietras K, Sjoblom T, Rubin K et al (2003) PDGF receptors as cancer drug targets. Cancer Cell 3:439–443CrossRefPubMed

17.

Cao R, Bjorndahl MA, Religa P et al (2004) PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6:333–345CrossRefPubMed

18.

Kodama M, Kitadai Y, Sumida T et al (2010) Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor beta is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 101:1984–1989CrossRefPubMed

19.

Ehnman M, Missiaglia E, Folestad E et al (2013) Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 73:2139–2149CrossRefPubMedPubMedCentral

20.

Hwang RF, Yokoi K, Bucana CD et al (2003) Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9:6534–6544PubMed

21.

Singh PK, Wen Y, Swanson BJ et al (2007) Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 67:5201–5210CrossRefPubMed

22.

Tsao AS, Wei W, Kuhn E et al (2011) Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-beta) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer 12:369–374CrossRefPubMedPubMedCentral

23.

Weissmueller S, Manchado E, Saborowski M et al (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 157:382–394CrossRefPubMedPubMedCentral

24.

Sobin LH, Gospodarowicz MK, Wittekind C et al (2010) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Hoboken

25.

Juliachs M, Munoz C, Moutinho CA et al (2014) The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res 20:658–667CrossRefPubMed

26.

Rhim AD, Mirek ET, Aiello NM et al (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148:349–361CrossRefPubMedPubMedCentral

27.

Chen H, Sun Y, Wu C et al (2012) Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer 19:321–331CrossRefPubMedPubMedCentral

28.

Gao L, Antic T, Hyjek E et al (2013) Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma. Cancer Cytopathol 121:644–652CrossRefPubMed

29.

Boone BA, Sabbaghian S, Zenati M et al (2014) Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer. J Surg Oncol 110:171–175CrossRefPubMed

30.

Higashi M, Yokoyama S, Yamamoto T et al (2015) Mucin Expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Pancreas 44:728–734CrossRefPubMedPubMedCentral

31.

Preis M, Gardner TB, Gordon SR et al (2011) MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 17:5812–5821CrossRefPubMedPubMedCentral

Title: Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer
Authors: Hiroshi Kurahara
Kosei Maemura
Yuko Mataki
Masahiko Sakoda
Hiroyuki Shinchi
Shoji Natsugoe
Publication date: 01-08-2016
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 8/2016
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-016-3477-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2016

Are Medical Students Who Want to Become Surgeons Different? An International Cross-Sectional Study: Reply

The Merits of a Two-Day Evidence-Based Medicine Course for Surgical Residents

What Kind of Incision Should be Used in Thoracic Trauma Patients in Emergent Cases?

Pre-surgical Administration of Microbial Cell Preparation in Colorectal Cancer Patients: A Randomized Controlled Trial

What Kind of Incision Should Be Used in Thoracic Trauma Patients in Emergent Cases? Reply

Laparoscopic Roux en-Y Gastric Bypass Using a Modified Retrocolic–Supracolic Approach: Outcomes from 300 Patients